Gross cytogenetic anomalies are traditionally being used as diagnostic, prognostic and therapeutic markers in the clinical management of cancer, including childhood acute lymphoblastic leukemia (ALL). Recently, it has become increasingly clear that genetic lesions driving tumorigenesis frequently occur at the submicroscopic level and, consequently, escape standard cytogenetic observations. Therefore, we profiled the genomes of 40 childhood ALLs at high resolution. We detected multiple de novo genetic lesions, including gross aneuploidies and segmental gains and losses, some of which were subtle and affected single genes. Many of these lesions involved recurrent (partially) overlapping deletions and duplications, containing various established leukemia-associated genes, such as ETV6, RUNX1 and MLL. Importantly, the most frequently affected genes were those controlling G1/S cell cycle progression (e.g. CDKN2A, CDKN1B and RB1), followed by genes associated with B-cell development. The latter group includes microdeletions of the B-lineage transcription factors PAX5, EBF, E2-2 and IKZF1 (Ikaros), as well as genes with other established roles in B-cell development, that is RAG1 and RAG2, FYN, PBEF1 or CBP/PAG. The fact that we frequently encountered multiple lesions affecting genes involved in cell cycle regulation and Bcell differentiation strongly suggests that both these processes need to be targeted independently and simultaneously to trigger ALL development.
Introduction
Owing to advances in therapeutic regimens developed during the last two decades, the majority of children with acute lymphoblastic leukemia (ALL) respond well to therapy. Approximately 25% of the patients, however, still suffer from relapse, which diminishes the chances of complete cure considerably. 1 Early-stage identification of this latter subgroup of patients could eventually translate into a significantly improved overall outcome for ALL patients.
In ALL, chromosome aneuploidies and recurrent chromosomal translocations are of considerable prognostic importance, and are routinely used in the course of clinical decision making. For example, patients with high hyperdiploidy (450 chromosomes), which occurs in B25% of the children diagnosed with ALL, generally respond well to chemotherapy and are thus associated with a relatively good prognosis, whereas the outcome of patients with hypodiploidy (o45 chromosomes) is generally poor. 2, 3 Furthermore, the presence of a recurring t(12;21)(p13;q22) translocation, resulting in ETV6-RUNX1 gene fusions (20-25%) , is usually associated with a relatively good prognosis, whereas the t(9;22)(q34;q11)-associated BCR-ABL gene fusions (2-6%) and 11q23-associated MLL rearrangements relate to a poor prognosis. 1, 4 Besides their use as integrated diagnostic tools, individual genomic anomalies may represent critical, deregulated pathways in leukemogenesis, which might be used as targets for existing or newly developed (combinations of) drugs. However, although the identification of the genes involved in the t(9;22) translocation has ultimately resulted in the development of an effective new drug (i.e., Imatinib), 5 for most poor prognosisrelated cytogenetic anomalies the pathophysiology behind the poor response to therapy awaits further elucidation. Detailed knowledge of the chromosomal aberrations related to the initiation and subsequent progression (including the development of therapy resistance) of ALL may provide new insights into the various (alternative) processes underlying leukemogenesis and disease pattern of pediatric ALL. Intermediate size (10 kb-5 Mb) genomic anomalies have thus far escaped diagnostic notion as techniques facilitating the high-throughput detection of such anomalies have only recently become available.
In this study we used high-resolution array comparative genomic hybridization (CGH) with single-nucleotide polymorphism (SNP)-based oligonucleotide arrays for a comprehensive analysis of copy number aberrations in 40 childhood ALLs. Using this approach, we were able to confirm most cytogenetically pre-established anomalies and, in addition, identified several (novel) submicroscopic aberrations affecting genes suspected to contribute to leukemogenesis in these ALLs.
Materials and methods

Patient material and DNA isolation
All patient material was obtained with informed consent from the Dutch Childhood Oncology Group (DCOG), and was part of a treatment protocol recently started in The Netherlands (ALL-10). The diagnosis of ALL was confirmed at the DCOG; 33 patients suffered from precursor B-cell ALL and seven patients from T-lineage ALL. Cells were harvested from peripheral blood or bone marrow aspirates and DNA was isolated using a QiaAmp purification kit (Qiagen, Venlo, The Netherlands). Male and female reference DNA pools, previously used for tilingresolution BAC array analysis, 6 were used for single-color hybridization to the Affymetrix SNP oligonucleotide microarrays. These reference pools contain equal amounts of genomic DNA from 10 healthy donors (male or female). For all microarray experiments, two male and two female reference pools were used for normalization purposes.
Affymetrix single-nucleotide polymorphism array CGH
The Affymetrix 500 k mapping array set comprises two arrays, each containing approximately 250 000 SNPs (www.Affymetrix. com). For this study, we selected the 250 k Nsp SNP array, which contains 262 264 SNPs each represented by 24 or 40 25-mer oligonucleotides. Three samples were analyzed on 50 k XbaI or HindIII arrays. Array experiments were performed according to protocols provided by the manufacturer (Affymetrix Inc., Santa Clara, CA, USA). Briefly, 250 ng of total genomic DNA was digested with the appropriate restriction enzyme, ligated to adaptors and amplified by a generic primer. After purification, the amplified DNA was digested with DNase I, labeled with biotin and hybridized onto the microarray. Hybridized probes were captured by streptavidin-phycoerythrin conjugates after which the array was scanned and genotypes were determined as described. 7 
Data analysis
Genomic copy numbers were calculated using the public domain software package CNAG (Copy Number Analyzer for Affymetrix GeneChip Mapping arrays), Version 2.0. 8 The underlying algorithm of CNAG strongly improves the signalto-noise ratios of the final copy number output by (i) correcting for length and GC content of the individual polymerase chain reaction (PCR) products using quadratic regressions and by (ii) providing fully automated optimal sample selection. Copy number aberrations were scored using the Hidden Markow Model available within the CNAG software package as well as by visual inspection.
All aberrations identified in this way were compared to those observed in a cohort of 130 non-leukemic-unrelated individuals, and were queried against an extensive up-to-date list with previously established polymorphic genomic regions 9 (http:// projects.tcag.ca/variation/) in order to exclude aberrations representing normal copy number variations. Degrees of overlap among the remaining true aberrations were visualized subsequently using the standard Microsoft Excel software package.
To identify genomic intervals showing copy-neutral loss of heterozygosity (LOH) with potential relevance in leukemogenesis, regions 41 Mb consisting of continuous stretches of homozygous SNP calls were scored for their degree of overlap with regions of recurrent copy number loss in ALLs and/or for the presence of genes with a previously established functional relevance in leukemia. Regions frequently found to be homozygous in the cohort of 130 non-leukemic unrelated individuals were omitted from this analysis.
Fluorescent in situ hybridization
The 5q33.3 microdeletion in case 9442 was validated by fluorescent in situ hybridization (FISH) analysis on methanol/ acetic acid-fixed bone marrow cells. Slide preparation and (post)-hybridization was carried out using a standard protocol. Subsequently, BAC clones RP11-4J6 and RP11-47G17 (BACPAC Resources, Oakland, USA), representing the EBF gene at 5q33.3, were labeled with biotin and immunocytochemically stained with FITC. As a reference, a 5q telomere probe directly labeled with rhodamin was used (MB Biomedicals Europe, Illkirch, France). Visual examination of the slides was performed using a Zeiss Axiophote-2 microscope equipped with appropriate filters. Digital images were captured using a high-performance Leica DC 350FX camera coupled to Leica CW 4000 software package.
Results and discussion
Affymetrix SNP arrays detect multiple genetic lesions in pediatric ALL samples
For the high-resolution analysis of copy number aberrations in pediatric ALL, we selected 40 patients who were diagnosed with precursor B-cell ALL (n ¼ 33) or T-ALL (n ¼ 7), and treated according to a recently started ALL trial (ALL-10 protocol) of the DCOG. The group of precursor B-cell ALL samples included patients with high hyperdiploidy (n ¼ 9), low hyperdiploidy (n ¼ 7) and hypodiploidy (n ¼ 3). Two patients had a confirmed MLL rearrangement, including one with a t(4;11) translocation. Other recurrent translocations included t(1;19) and t(12;21) ( Table 1 ). DNA isolated from peripheral blood or bone marrow samples (leukemic blast counts are listed in Supplementary  Table 1 ) was labeled and hybridized to SNP-based genotyping arrays from Affymetrix. Subsequently, all genomic profiles were scored for copy number gains or losses and for copy-neutral regions exhibiting extended stretches of homozygosity. Using this approach, we were able to accurately detect various genomic anomalies that are typical for ALL.
Apart from whole chromosome aneuploidies present in hyperdiploid and hypodiploid cases, multiple lesions were detected varying from loss or gain of complete chromosome arms (often associated with recurrent chromosomal translocations) to microdeletions and microduplications targeting genomic intervals as small as 32 kb in size. The lesions identified included many regions harboring genes that are well-established targets in leukemogenesis. For example, the most frequent anomaly in B-lineage ALLs, which we found in 24% of the precursor B-cell ALLs but not in T-ALLs, involved the ETS family transcription factor gene ETV6 (TEL). These anomalies ranged from loss of larger parts of the p-arm of chromosome 12, to focal microdeletions encompassing or disrupting the ETV6 gene. In two cases, disruption of the gene was caused by a recurrent unbalanced t(12;21)-associated ETV6-RUNX1 gene fusion (Table 1) , which is known to contribute to leukemogenesis. 10 Also, amplification of chromosome 21 (predominantly tetrasomy 21) was recurrently found in precursor B-cell ALLs, occurring in another 19% of the cases. Although this region also includes the RUNX1 gene, recent expression studies on ALL cases with amplification of chromosome 21 did not reveal any significant overexpression of RUNX1, suggesting that this gene may not be the prime target within this region. 11 Other major abnormalities that we detected in precursor B-cell ALLs were gains of 1q (multiple loci), 9q and 17q, and loss of 1p (Table 2 ). Since we found no overlap in the interstitial deletions occurring in 1p, it appears that there is no functional selective pressure (gene) driving the observed losses of these regions. Another recurrently deleted interval (encompassing 6q16.3-21) was found in both B-and T-ALLs. Multiple genes previously postulated as positional functional candidate targets were located within the minimal overlapping region, including the cyclin C gene, the GRIK2 gene, the B-cell surface marker CD24 gene, the Kruppel-like Zinc finger BLIMP1 gene and the protein tyrosine kinase FYN gene. [12] [13] [14] [15] Considering the frequent occurrence of this 6q deletion and the absence of more subtle (submicroscopic) lesions targeting only one of the above genes, it is reasonable to assume that multiple genes within this interval contribute to ALL development. On average we found 4.2 lesions per case in the precursor B-cell ALLs (3.1 losses and 1.1 gains), and 2.6 lesions per case in the T-ALLs (1.7 losses and 0.9 gains) studied. Taken together, we conclude that multiple independent copy number aberrations are frequently observed in individual cases of childhood ALL, suggesting that complementary genetic lesions are required to develop a full-blown leukemia.
Conformity between karyotyping and SNP-based array CGH
In 30 of the 40 patients included in this study, verified karyotypes were available for direct comparison with the SNPbased array CGH profiles generated (Supplementary Table 1 ). As expected, most regions of aneuploidy, including segmental chromosome gains and losses, which were detected with classical cytogenetics could also be detected with SNP-based array CGH. The only exceptions turned out to be anomalies observed in a minor sub-fraction of the metaphases of which the percentage in the pool of leukemic blasts (which includes the non-dividing cells) was below detection level for array CGH. On the other hand, whereas classical cytogenetics remained incomplete in five of the 30 ALL samples due to lack of metaphases or metaphases that were hard to interpret, array CGH data were informative in all cases, and the breakpoints flanking the aberrations could precisely be mapped, often at the single-gene level. As a result, all previously reported unbalanced translocations could be confirmed. In one case, with a FISHverified 11q23-associated translocation, both translocation breakpoints could even be fine mapped due to microdeletions within the MLL gene at 11q23 and the AF6 (MLLT4) gene at 6q27 ( Table 1) . As a consequence, the cytogenetic description for this latter case could be refined to t(6;11)(q27;q23). In two independent translocation cases with losses of part of 9p, the breakpoints at 9p13.2 could be positioned within the first intron of a gene, that is the zinc finger ZCCHC7 gene of which the expression was found to be increased during early B-cell development, 16 indicating that this gene may also be implicated in recurrent gene fusions. Indeed, very recently the ZCCHC7 gene has been reported as a fusion partner of MYC in a B-cell lymphoma carrying a t(8;9)(q24;p13) translocation. 17 Together, these findings illustrate that high-resolution SNP-based array CGH allows for a comprehensive inventory of copy number changes in childhood ALLs that are in conformity with, and further refine, routine cytogenetic analysis.
Copy-neutral LOH
Besides the identification of copy number alterations, SNPbased genotyping also enables the detection of extended stretches of copy-neutral LOH. Regions exhibiting such LOH contain identical segments of genomic DNA that originate from one parental homologue, known as uniparental disomy (UPD) 18 and, if occurring before or during the clonal expansion of oncogenic blasts, may harbor homozygous recessive mutations in tumor suppressor genes crucial for leukemogenesis, as was recently demonstrated in AML. 19 However, we noticed that small regions of homozygosity (o5 Mb) frequently occurred in both our childhood ALL samples as well as in a panel of 130-unrelated non-leukemic control samples, and that these regions were overlapping for B80%. Furthermore, in a similar study on myelodysplastic syndrome (to be published elsewhere), we observed that all of the copy-neutral LOH regions o5 Mb were also present in matching non-neoplastic cells, which indicates that such small LOH regions are congenital, and might be inherited regions of copy-neutral LOH segregating within a given population. Larger regions of copy-neutral LOH (45 Mb) were less frequent, occurring only in 13 cases (usually 1-2 regions per sample), and appeared to be randomly distributed throughout the genome. None of these regions of copy-neutral LOH overlapped with any of the smaller deletions observed in the other cases, thus hampering the identification of additional candidate tumor suppressor genes. However, since we did find two cases harboring a homozygous deletion within a region of LOH, namely the CDKN2A locus at 9p21.3 and the E2-2 locus at 18q21.2 (see below), a scenario in which bi-allelic inactivation of the ALL-associated genes occurs by replacing the wildtype allele by a copy of the other, mutated allele (either by point mutations or microdeletions), may be more common in leukemogenesis than previously assumed.
Sub-microscopic lesions affecting single genes are frequent in childhood ALL Subtle (o1.5 Mb) lesions encompassing single, or only a few genes were observed with relative high frequencies (Table 3;  Supplementary Tables 2 and 3) , which allowed us to translate our findings directly into biological pathways that might be involved in childhood ALL development. Many of these copynumber alterations could be associated with cellular proliferation, survival and/or apoptosis. Examples include the transcription factor gene c-Myb and the B-cell translocation gene BTG1.
c-Myb appears to activate genes critical to cancer progression and metastasis. These genes include cyclooxygenase-2 (COX-2), Bcl-2, BclX(L) and c-Myc, which affect diverse growth regulatory processes and appear to play an important role in the control over proliferation and differentiation of hematopoietic progenitor cells. Remarkably, whereas others have reported the c-MYB locus to be recurrently deleted in ALL (Mullighan et al., ASH Annual Meeting Abstracts 2006; 108: 108), we found the entire gene to be located in a small (B180 kb) duplicon in one of the T-ALL cases. BTG1 is a negative effector of B-cell proliferation that is regulated by the BCL2 and FOXO3a genes. The observation that the BTG1 gene can apparently be targeted through both microdeletions and BTG1-MYC gene fusions indicates that, apart from c-Myc activation, loss of BTG1 function may contribute to leukemogenesis as well.
In general, our findings demonstrate that two major processes are commonly involved in the development of childhood ALL. These include relaxation of the G1/S cell cycle checkpoint and, in the major subgroup of precursor B-cell ALLs, a block in B-cell lineage differentiation. Below, both processes will be discussed in more detail.
Targeting of G1/S transition effectors in childhood ALL development
The most common aberration observed in our panel involves a well-characterized deletion at 9p21.3, encompassing CDKN2A (MTS1) and CDKN2B (MTS2), both of which are known to be frequently deleted in various malignancies, including ALL. 20 The CDKN2A gene encodes two distinct proteins, p16
INK4a and p14 ARF both established cell cycle regulators. p16 INK4a acts as an inhibitor of the cyclin-dependent kinase 4/CyclinD complex, thereby mediating phosphorylation of the retinoblastoma protein RB1 and concomitant cell cycle progression, whereas p14 ARF prevents degradation of p53 by interacting with the MDM2 protein. 21, 22 The CDKN2B gene encodes the p15
INKb protein, a gene implicated in TGFb-induced cell cycle arrest. 23 We found this region to be deleted in 30% of the cases, and more prominently in T-ALLs (71%, n ¼ 5) than in precursor Bcell ALLs (21%, n ¼ 7) (Table 3) . Bi-allelic loss of the CDKN2A locus was found in four cases, and was caused either by a loss of one 9p arm and a microdeletion of the second allele (three cases), or by a (presumed) conversion of a duplicated 9p arm carrying a 9p21.3 microdeletion onto the normal chromosome 9 (one case), resulting in UPD of most of the 9p arm and translating into a fully homozygous microdeletion. Within our ALL cohort, the CDKN2A and CDKN2B genes were always codeleted, whereas the MTAP gene, located distal to the CDKN2A gene, was located outside the deletion in one of the cases. These observations are completely in line with previous studies, which have indicated that in pediatric ALL only the CDKN2A gene appears to be the critical target in this region. 20 Although the frequency of CDKN2A deletions was lower in precursor B-cell ALLs as compared with T-ALLs, many other modulators of G1/S cell cycle progression were found to be affected (Figure 1 ). For example, deletion of the RB1 gene at 13q14.2 was observed in three precursor B-cell ALLs, two of which did not exhibit a CDKN2A deletion, and one ALL with a 13q loss and a focal (1.5 Mb) deletion of the RB1 gene on the other allele. Other genes affecting G1/S cell cycle progression, either directly or indirectly, included those encoding the cell cycle inhibitors CDKN1B (p27 KIP ) and CDKN2C (p18 INK4C ), the Forkhead family transcription factor FOXO3a, the F-Box and WD-40 domain protein 7 FBXW7 (CDC4), and the cellular repressor CREG1 (Cellular Repressor of E1A-stimulated Genes) (Figure 1 ; Tables 2 and 3 ). FOXO3a, which is known to be involved in many cellular processes such as proliferation, apoptosis and DNA repair, can act as an inducer of p27 Kip1 expression, 24 whereas the FBXW7 protein targets both cyclin E and c-Myc for ubiquitin-mediated degradation. 25, 26 CREG1 antagonizes the cellular transformation by E1A and Ras in primary tissues and was shown to repress cellular growth and differentiation by generating an upregulation of p27 Kip1 . 27, 28 Taken together, copy number losses affecting genes involved in G1/S phase progression were found in 60% of the childhood ALLs, namely in 54% of the precursor B-cell ALLs and 86% of the T-ALLs. These data indicate that a reconditioned G1/S cell cycle progression is frequently observed in ALL, and involves more, functionally tightly clustered, genes than previously anticipated.
Genetic lesions affecting B-cell lineage commitment and differentiation
In addition to genes affecting cell cycle progression in the precursor B-cell ALLs, we frequently observed copy number alterations affecting genes involved in early B-cell differentiation. These include four transcription factors known to play a key role in B-lineage specification, that is the paired box gene PAX5 (n ¼ 8), the early B-cell factor gene EBF (n ¼ 2), the E2-2 gene (n ¼ 2) and the IKZF1 (Ikaros) gene (n ¼ 1) (Figure 2a and Table 3 ). Pax5 is a critical determinant of B-lineage commitment that restricts the developmental options of early progenitors to the B-cell pathway by activating B-lineage-specific genes and Only fully annotated genes are incorporated in this list. c Selection of candidate genes is based on their presumed role in leukemogenesis; genes involved in B-cell development are underlined and novel targets are in bold, Rb1 microdeletions were recently reported by Strefford et al. repressing genes of other lineage-specific differentiation programs. 29 Microdeletions at 9p13.2 were identified in four precursor B-cell ALL cases, in three of which PAX5 was the only gene affected, indicating that this gene is a critical target in the development of precursor B-cell ALL. The expression of PAX5 is directly regulated by EBF and E2A, two transcription factors that cooperatively regulate many genes involved in Bcell differentiation and immunoglobulin (Ig) gene recombination. 30 Two B550 kb microdeletions at 5q33.1 encompassed the entire EBF gene as the only gene affected (Figure 2b ). In one of these cases, confirmed the deletion by FISH in both leukemic blast metaphases (Figure 2c ) and B60% of interphase nuclei.
Microdeletions affecting the E2A gene were not observed in our (limited) set, but the recurrent t(1;19)-associated E2A-PBX1 gene fusion that was detected (discussed above), and which occurs in 4-5% of the childhood ALLs, is known to have oncogenic properties in lymphoblastic leukemias. 31 Furthermore, two of the hypodiploid precursor B-cell ALL cases showed loss of the entire chromosome 19. The observation that both E2a and Ebf heterozygous mice display an impairment of B-cell development indicates that both these genes act in a dosedependent manner 32, 33 and, thus, that loss of one allele as observed in the two precursor -B-cell ALL cases may lead to a B-cell-associated haploinsufficiency.
In two pre-B-cell ALL cases, we detected small non-overlapping microdeletions affecting the E2A-related E-protein family member E2-2 at 18q21.2 ( Figure 3 ). E2-2 is a basic helix-loop-helix transcription factor that is differentially expressed during B-cell development and is required for optimal expansion of pro-B cells. 16, 34 Two E2-2 deletions that we found resulted in disruption of the gene. In one case (case 9385), the deletion included the promoter region and the first three exons of the gene, whereas in the second case (case 9333) a B30-70 kb intragenic homozygous deletion was detected removing exon 6 of the E2-2 gene. The latter subtle (single-exon) deletion was subsequently validated by PCR (Figure 3) , and results in a disruption of the open reading frame on both alleles. As was observed for the CDKN2A locus at 9p21.3 (see above), the presence of identical deletions on both E2-2 alleles in this patient was due to copy-neutral LOH of 18q21.2-qter. Finally, the IKZF1 gene encodes a zinc finger transcription factor that is required for the earliest stages of lymphoid lineage commitment (Figure 2a) , and is expressed in both stem cells and multipotent progenitors. 35 We detected a B250 kb microdeletion encompassing almost the entire IKZF1 gene in one precursor B-cell ALL sample. Two additional cases exhibited a loss of one IKZF1 allele due to a monosomy for chromosome 7. Collectively, deletions of one or more B-cell . Indicated are the differentiation-related genes, including critical lineage-determining transcription factors (above arrows, for reviews see 30, 45, 46 ). Gene positions are mainly based on differential expression levels according to Zelm et al. 16 Boxed genes were found as deletions in one or more ALL samples. lineage-associated genes were observed in 27% of the pre-B-cell ALLs.
Other factors associated with B-cell developmental processes were found to be affected by copy number changes as well. For example, V(D)J recombination is known to create diversity among Ig and T-cell receptor proteins in lymphoid cells. 36 Two key mediators in this process, the recombination assembly genes RAG1 and RAG2, act together to provide double-stranded breaks required for this type of programmed genomic rearrangements. We found loss of the RAG1/2 locus in four precursor B-cell ALL cases, which indicates that defects in this process contribute to leukemogenesis. Another frequently deleted gene (n ¼ 5; Table 2 ) encodes the protein tyrosine kinase FYN, an important regulator of early B-cell development. 37 In addition, we found the transmembrane adaptor protein CBP/PAG, a known interactor of FYN, to be affected by a microdeletion (8q21.13) in an additional case of precursor B-cell ALL (Table 3) . Although mouse studies have demonstrated that CBP/PAG is not essential for B-and/or T-cell development, 38 a deficiency in this gene may nevertheless contribute to oncogenesis in the lymphoid lineage. Interestingly, also CREG may play a role in B-cell development, since the CREG1 gene was found to be one of the most prominent target genes of the B-cell-specific BOB.1/OBF.1 transcriptional coactivator, which is critical at different stages of B-cell development. 39 Finally, we detected a sub-microscopic gain of a small region on 7q22.3, containing the pre-B-cell colonyenhancing factor/Visfatin gene (Table 3) , an interferon-gamma inducible cytokine acting on early B-cell precursors. [40] [41] [42] We conclude that genes controlling early B-cell lineage commitment and differentiation are affected by (micro) deletions in at least 42% of the pediatric precursor B-cell ALLs investigated.
Conclusions
Our high-resolution SNP-based genomic profiling of 40 independent cases of childhood ALL has facilitated the identification of several novel cytogenetic aberrations that are likely to be functionally related to the process of leukemogenesis. Our array CGH data are in close agreement with routine karyotyping data and, in addition, lead to a significant refinement thereof. Many of the lesions detected represented focal deletions containing few (in some cases even single) genes, including genes with an established and critical role in leukemogenesis such as CDKN2A, ETV6 (TEL), RUNX1 (AML1) and genes, such as MLL, that are used to stratify the patients. Therefore, we conclude that high-resolution SNP-based array CGH is a reliable and powerful tool for the identification of (novel) genes related to transformation of lymphoid cells and bio-markers relevant for the diagnosis, prognosis and treatment of childhood ALL. During the preparation of this article, we became aware of a parallel SNP-based array CGH study using a similarly selected cohort of childhood ALLs (Mullighan et al., ASH Annual Meeting Abstracts 2006; 108: 108). Interestingly, findings summarized in this meeting abstract appeared to be highly compatible with our current study, including similar frequencies of CDKN2A deletions in T-ALLs (B70%) and precursor B-cell ALLs (20-30%). Moreover, many of the novel recurrent as well as unique lesions that we identified (including EBF, IKZF1, BTG1, RB1) were also detected by Mullighan et al., which confirms the validity of our present observations. Although approximately 75% of the childhood ALLs show known recurrent cytogenetic lesions, 2 our data reveal that additional hits appear to be required for lymphocytes in order to transform into full-blown leukemic cells. This observation is in agreement with earlier findings indicating that recurrent gene fusions contribute to, but may not be sufficient for, leukemogenesis. 10, 43 In the majority of the B-lineage ALLs included in our cohort, genetic defects that cause a block in lymphocyte differentiation and progression of G1/S cell cycle transition were most common, and these lesions co-occured as copy number changes in at least 57% of the cases. This illustrates that multiple hits in these two pathways may act as a highly efficient mechanism for blast transformation. In fact, since defects in these genes may also include inactivating (point) mutations, 44 the significance of such defects in ALL development may even be more pronounced.
Based on these results, we conclude that high-resolution SNPbased genomic profiling is highly suitable for the identification of genomic anomalies and genes relevant for the development of childhood ALL. Future studies, using larger cohorts of ALL samples, may allow a refined classification of these copy number anomalies and may further help to delineate signaling pathways that can be employed for the development of novel targeted therapies.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu). The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number GSE 7255.
